Table 1.
TMS stimulation intensities and baseline measurements.
| Experimental session | SI 1mv (%MSO) | Baseline MEP (mV) | |||
|---|---|---|---|---|---|
| BL1 | BL3 | BL1 | BL2 | BL3 | |
| PLC+ PLC | 48.68 ± 10.55 | 48.90 ± 10.63 | 1.04 ± 0.06 | 0.98 ± 0.12 | 1.01 ± 0.07 |
| 50 mg CYC + PLC | 48.22 ± 9.02 | 48.5 ± 9.03 | 1.02 ± 0.08 | 1.00 ± 0.09 | 1.00 ± 0.05 |
| 100 mg CYC + PLC | 48.59 ± 9.55 | 48.59 ± 9.58 | 1.03 ± 0.07 | 1.00 ± 0.08 | 1.00 ± 0.06 |
| 200 mg CYC + PLC | 48.59 ± 9.26 | 48.40 ± 9.05 | 0.99 ± 0.06 | 1.06 ± 0.19 | 1.00 ± 0.07 |
| PLC + bromocriptine | 48.22 ± 9.18 | 47.95 ± 8.91 | 1.00 ± 0.01 | 1.02 ± 0.17 | 0.99 ± 0.05 |
| 50 mg CYC + bromocriptine | 48.59 ± 9.98 | 48.59 ± 9.60 | 1.03 ± 0.06 | 1.03 ± 0.17 | 1.01 ± 0.07 |
| 100 mg CYC + bromocriptine | 48.86 ± 9.37 | 48.59 ± 9.48 | 1.03 ± 0.04 | 1.07 ± 0.13 | 1.02 ± 0.02 |
| 200 mg CYC + bromocriptine | 48.36 ± 10.27 | 48.5 ± 10.538 | 0.98 ± 0.06 | 0.99 ± 0.17 | 1.01 ± 0.03 |
| PLC + L-Dopa | 47.59 ± 9.86 | 47.59 ± 9.85 | 1.05 ± 0.07 | 1.02 ± 0.06 | 1.02 ± 0.05 |
| 50 mg CYC + L-Dopa | 47.63 ± 9.54 | 48.04 ± 10.46 | 1.00 ± 1.00 | 1.01 ± 0.17 | 1.02 ± 0.05 |
| 100 mg CYC + L-Dopa | 47.40 ± 7.83 | 47.86 ± 8.43 | 1.00 ± 0.04 | 0.94 ± 0.11 | 1.00 ± 0.07 |
| 200 mg CYC + L-Dopa | 47.63 ± 8.51 | 47.72 ± 8.59 | 1.03 ± 0.06 | 0.99 ± 0.13 | 1.00 ± 0.05 |
SI1mV refers to the maximal stimulator output (%MSO) that was required for generating ~1 mV MEP. BL1 refers to the baseline MEPs measured at the beginning of each session, BL2 refers to the baseline MEPs measured 2 h after medication, and BL3 refers to the last baseline measurement, including required TMS intensity adjustments. The results of the ANOVAs indicate no significant differences between baseline MEP and SI1mV before and after medication between sessions. Data are presented as mean ± SD.